- Aptorum Group Limited announced a registered direct offering for the purchase and sale of **1,000,000 Class A ordinary shares** at a price of **$2.00 per share**.  **[1734005_0001213900-25-099575_ea026130601ex99-4_aptorum.htm:0]** 
- In a concurrent private placement, the company will issue unregistered warrants to purchase up to **2,000,000 Class A ordinary shares** at an exercise price of **$2.00 per share**.  **[1734005_0001213900-25-099575_ea026130601ex99-4_aptorum.htm:0]** 
- The gross proceeds from the offering are expected to be **$2 million**, with an additional potential **$4 million** if the unregistered warrants are fully exercised.  **[1734005_0001213900-25-099575_ea026130601ex99-4_aptorum.htm:0]** 
- The net proceeds, estimated at approximately **US$1.725 million**, are intended to fund expenses related to the previously announced merger agreement with DiamiR Biosciences Corp. and for general working capital.  **[1734005_0001213900-25-099575_ea026130601ex99-4_aptorum.htm:0]** **[1734005_0001213900-25-099575_ea0261306-6k_aptorum.htm:1]** 
- The offering closed on **October 14, 2025**.  **[1734005_0001213900-25-099575_ea0261306-6k_aptorum.htm:1]**

Aptorum Group Announces Registered Direct Offering

- DiamiR Biosciences Corp. reported a **net loss of $(283,700)** for the three months ended August 31, 2025, compared to $(176,275) for the same period in 2024.  **[1734005_0001213900-25-099193_ea026060301ex99-1_aptorum.htm:0]** 
- Total revenue for Q3 2025 was **$99,878**, entirely from service revenue, a decrease from **$208,843** in grant revenue during the prior year period, as grant funding was exhausted in January 2025.  **[1734005_0001213900-25-099193_ea026060301ex99-1_aptorum.htm:0]** **[1734005_0001213900-25-099193_ea026060301ex99-2_aptorum.htm:3]** 
- In **July 2025**, DiamiR entered into a definitive **merger agreement with Aptorum Group Limited**, which, if completed, would result in DiamiR shareholders receiving shares of the surviving company.  **[1734005_0001213900-25-099193_ea026060301ex99-2_aptorum.htm:0]** **[1734005_0001213900-25-099193_ea0260603-6k_aptorum.htm:0]**  This merger activity contributed to a significant increase in general and administrative expenses to **$509,630** for the quarter.  **[1734005_0001213900-25-099193_ea026060301ex99-2_aptorum.htm:3]** 
- DiamiR received **CLEP Test Approval for its APOE Genotyping test** from the New York State Department of Health (NYSDOH) in **August 2025** and renewed key licenses and accreditations, enabling it to offer new testing services.  **[1734005_0001213900-25-099193_ea026060301ex99-2_aptorum.htm:2]** 
- Management believes its current capital is **insufficient to fund operations for the next twelve months** and will need to raise additional capital.  **[1734005_0001213900-25-099193_ea026060301ex99-1_aptorum.htm:3]** **[1734005_0001213900-25-099193_ea026060301ex99-2_aptorum.htm:7]**

DiamiR Biosciences Corp. Reports Q3 2025 Results and Merger Agreement with Aptorum Group Limited

- Aptorum Group Limited reported a **significantly reduced net loss** of **$(441,780)** for the six months ended June 30, 2025, compared to **$(2,643,796)** for the same period in 2024, primarily driven by a substantial decrease in research and development expenses.  **[1734005_0001213900-25-096129_ea025636201ex99-1_aptorum.htm:1]** **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:5]** **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:7]** 
- The company entered into an **Agreement and Plan of Merger with DiamiR Biosciences Corp.** on July 14, 2025, with DiamiR stockholders expected to own approximately **70%** and existing Aptorum shareholders **30%** of the combined company, and the merger is anticipated to close in the **fourth quarter 2025**.  **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:1]** **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:4]** **[1734005_0001213900-25-096129_ea025636201ex99-1_aptorum.htm:15]** 
- Management has determined that conditions, including a net loss of **$449,295**, working capital of **$1,998,298**, and an accumulated deficit of **$72,871,308** as of June 30, 2025, raise **substantial doubt about the Company's ability to continue as a going concern** within one year.  **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:3]** **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:7]**

Aptorum Group (APM)